SILO PHARMA, INC. Recognition of Deferred Revenue
SILO PHARMA, INC. (SILO) reported Recognition of Deferred Revenue of $3.35 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-24.
Discontinued › Income Statement › Other Income
us-gaap:RecognitionOfDeferredRevenue · last filed 2023-03-24
- SILO PHARMA, INC. recognition of deferred revenue for the quarter ending 2022-12-31 was -$65.40K.
- SILO PHARMA, INC. recognition of deferred revenue for the quarter ending 2022-09-30 was $0.00.
- SILO PHARMA, INC. recognition of deferred revenue for the quarter ending 2022-06-30 was $0.00.
- SILO PHARMA, INC. recognition of deferred revenue for the quarter ending 2022-03-31 was $68.75K.
- SILO PHARMA, INC. recognition of deferred revenue for fiscal 2022 was $3.35K, a 95.12% decline from fiscal 2021.
- SILO PHARMA, INC. recognition of deferred revenue for fiscal 2021 was $68.75K.
| Period end | Recognition of Deferred Revenue 3 month | Recognition of Deferred Revenue 6 month | Recognition of Deferred Revenue 9 month | Recognition of Deferred Revenue 12 month |
|---|---|---|---|---|
| 2022-12-31 | -$65.40K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | -$65.40K derived: sum of 2 quarters · filed 2023-03-24 | -$65.40K derived: sum of 3 quarters · filed 2023-03-24 | $3.35K 10-K · filed 2023-03-24 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $0.00 derived: sum of 2 quarters · filed 2022-11-10 | $68.75K 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-01 | $68.75K 10-Q · filed 2022-08-01 | ||
| 2022-03-31 | $68.75K 10-Q · filed 2022-05-13 | |||
| 2021-12-31 | $68.75K 10-K · filed 2023-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |